PepGen Inc. (NASDAQ:PEPG) CEO Buys $47,725.00 in Stock

PepGen Inc. (NASDAQ:PEPG) CEO James G. Mcarthur bought 41,500 shares of the firm’s stock in a transaction that occurred on Tuesday, April 8th. The stock was purchased at an average cost of $1.15 per share, with a total value of $47,725.00. Following the completion of the transaction, the chief executive officer now owns 103,913 shares in the company, valued at approximately $119,499.95. This trade represents a 66.49 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

PepGen Stock Down 2.6 %

PEPG stock traded down $0.03 during trading on Wednesday, hitting $0.97. The company had a trading volume of 49,347 shares, compared to its average volume of 800,865. PepGen Inc. has a 1-year low of $0.89 and a 1-year high of $19.30. The firm has a 50-day moving average price of $1.71 and a 200-day moving average price of $4.21. The firm has a market cap of $31.84 million, a PE ratio of -0.33 and a beta of 1.42.

PepGen (NASDAQ:PEPG) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.13. Sell-side analysts anticipate that PepGen Inc. will post -2.73 earnings per share for the current year.

Institutional Trading of PepGen

Several hedge funds have recently made changes to their positions in PEPG. RTW Investments LP acquired a new position in shares of PepGen during the fourth quarter worth about $12,102,000. Millennium Management LLC increased its position in PepGen by 1,033.2% during the 4th quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock worth $594,000 after purchasing an additional 142,814 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of PepGen during the 4th quarter worth approximately $516,000. Bridgeway Capital Management LLC lifted its holdings in shares of PepGen by 103.1% in the 4th quarter. Bridgeway Capital Management LLC now owns 98,900 shares of the company’s stock valued at $375,000 after buying an additional 50,200 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of PepGen by 442.5% in the fourth quarter. Deutsche Bank AG now owns 44,735 shares of the company’s stock valued at $170,000 after buying an additional 36,489 shares in the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of PepGen in a research note on Monday, February 24th. Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research report on Monday, December 16th.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.